LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Puma Biotechnology Inc

Închisă

SectorSănătate

3.3 0.3

Rezumat

Modificarea prețului

24h

Curent

Minim

3.26

Maxim

3.37

Indicatori cheie

By Trading Economics

Venit

-16M

3M

Vânzări

-13M

46M

P/E

Medie Sector

4.295

50.291

EPS

0.1

Marjă de profit

6.464

Angajați

172

EBITDA

-14M

4M

Recomandări

By TipRanks

Recomandări

Vânzare

Prognoză pe 12 luni

-9.37% downside

Dividende

By Dow Jones

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

7M

166M

Deschiderea anterioară

3

Închiderea anterioară

3.3

Sentimentul știrilor

By Acuity

50%

50%

154 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 iun. 2025, 23:49 UTC

Câștiguri

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 iun. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 iun. 2025, 21:30 UTC

Câștiguri

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Câștiguri

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 iun. 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 iun. 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 iun. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 iun. 2025, 23:33 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 iun. 2025, 23:30 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 iun. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 iun. 2025, 23:19 UTC

Achiziții, Fuziuni, Preluări

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 iun. 2025, 22:06 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:15 UTC

Câștiguri

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 iun. 2025, 21:07 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 iun. 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 20:52 UTC

Câștiguri

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 iun. 2025, 20:51 UTC

Câștiguri

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-9.37% jos

Prognoză pe 12 luni

Medie 3 USD  -9.37%

Maxim 4 USD

Minim 2 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Vânzare

2 ratings

0

Cumpărare

1

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

3.07 / 3.075Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

154 / 380 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.